PGM2L1 and neoplasm: A series of potential biomarker genes shared with blood- and skin-derived SCs were identified, including reported (TOX, DNM3, and KLHL42) and novel (PGM2L1 and SESN3) tumor-associated genes, which could help to differentiate between SS and erythrodermic inflammatory dermatoses (EIDs), and facilitate the diagnosis and prognosis of MF/SS.